However, patients on cinacalcet with hypertension (HYT) or diabetes mellitus plus hypertension (DM + HYT) as the underlying etiology showed a marginally significant reduction in hazard ratios ( p = 0.05 and 0.04, respectively).
Analysis of subgroups revealed that younger patients exhibited a higher hazard of first cardiovascular events compared to older patients, while males showed a trend toward modest protection against cardiovascular-related hospitalizations.
He also added that patients randomized to cinacalcet experienced fewer nonatherosclerotic cardiovascular events, while the effect of cinacalcet on atherosclerotic events did not reach statistical significance [ 30 ].